The most recent Form 13F filing that Trust Financial Corporation made with the SEC indicates that the company increased its holdings in Teva Pharmaceutical Industries Limited (NYSE: TEVA) during the third quarter. This information comes from the filing that the company made. The mutual fund finished with a total holding of 159,361 shares of the company’s stock, having purchased an additional 25,472 shares throughout the time. Trust Financial Corporation had stakes in Teva Pharmaceutical Industries with a total value of $1,286,000 at the end of the most recent reporting period.
Recently, transactions involving the company’s stock have taken place with other hedge funds. These transactions involved the company. BlackRock Inc. increased the percentage of Teva Pharmaceutical Industries stock owned by 3.7% during the year’s first three months. BlackRock Inc. now has a total of 41,648,716 shares of the company’s stock, which are currently valued at $391,081,000 following the purchase of an additional 1,494,814 shares during the most recent quarter. Call Insurance Enterprises Holdings Ltd. raised the amount of Teva Pharmaceutical Industries stock owned by 8.1% over the second quarter of this year. After making additional purchases totaling 1,424,200 shares during the most recent fiscal quarter, Clal Insurance Enterprises Holdings Ltd. now holds a total of 18,962,766 of the company’s shares, which have a value of $138,282,000. Harel Insurance Investments & Financial Services Ltd. increased the percentage of Teva Pharmaceutical Industries stock that it owns in the company by 9.3 percent over the second quarter. As a result of the purchase of 970,800 additional shares during the most recent fiscal quarter, Harel Insurance Investments & Financial Services Ltd. now owns 11,447,527 shares of the company. Based on the current market price, this gives the company a value of $86,085,000. During the second quarter, Credit Suisse AG made a 2.0% increase in the amount of Teva Pharmaceutical Industries stock held in its portfolio. Following purchasing 137,322 additional shares during the most recent quarter, Credit Suisse AG now directly owns 6,894,374 shares of the company’s stock. Based on the stock’s current market price, this gives the company a value of $51,847,000. And finally, during the first three months of this year, Dimensional Fund Advisors LP increased the size of its existing position in Teva Pharmaceutical Industries by purchasing an additional 13.9% of the company’s shares. After making additional purchases totaling 732,558 shares during the most recent fiscal quarter, Dimensional Fund Advisors LP now holds 6,006,352 of the company’s shares in its portfolio. There is a value of $56,399,000 attached to these shares. Institutional investors and hedge funds currently hold 50.39% of the company’s outstanding shares.
Recent activity on the part of several market observers suggests that they focus on TEVA shares.
The rating for Teva Pharmaceutical Industries was upgraded from “neutral” to “sell” in a research note issued by the UBS Group on November 4 and published that same day. The price objective for Teva Pharmaceutical Industries was lowered from $11.00 to $10.00. The company was given a “market perform” rating in a report distributed by BMO Capital Markets on Monday, November 7. BMO Capital Markets distributed the report. The investment bank JPMorgan Chase & Co. changed its rating on Teva Pharmaceutical Industries on November 14 from “neutral” to “underweight” in a research note made public by the company. They lowered their price objective for the stock from $11.00 to $10.00, having previously set it at $11.00. StockNews.com started providing coverage of shares of Teva Pharmaceutical Industries on Wednesday, October 12, within a research report released that day. They suggested that an interested party purchase the company. Jefferies Financial Group reaffirmed their “buy” rating on shares of Teva Pharmaceutical Industries and set a price objective of $10.00 for the company in a research report published on Friday, October 21. The report was released in conjunction with the company’s earnings release. The financial experts who have examined the stock have collectively assigned it five buy ratings, three hold ratings, and three sell recommendations. The consensus among market analysts is that investors should keep their “Hold” positions even though the stock price is currently anticipated to rise to $10.44 in the not-too-distant future.
Thursday marked the beginning.